Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Silence – Nobels and whistles

This article was originally published in Scrip

Executive Summary

The 2011 Nobel Prize in Medicine was awarded on 3 October to Bruce Beutler and Jules Hoffmann for discoveries in innate immunity, and to Ralph Steinman for his discovery of the dendritic cell and its role in adaptive immunity. While the headline news is that Steinman's award will proceed even though he died (on 30 September) without knowing of the prize, the timing of the award can serve to remind those in the life sciences that good science – even Nobel-quality science – is not a surrogate for or predictor of subsequent commercial success.

You may also be interested in...



Stockwatch: The Lexicon Of Biotech Survival

Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.

Stockwatch: Pandemic Cuts Deep Into Early Commercial Biotech

Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.

Stockwatch: GSK And AstraZeneca Rush Into Each Other’s Back Yards

It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel